X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (19110) 19110
Publication (957) 957
Book Review (247) 247
Newsletter (136) 136
Book Chapter (103) 103
Magazine Article (64) 64
Newspaper Article (48) 48
Conference Proceeding (17) 17
Book / eBook (16) 16
Dissertation (10) 10
Trade Publication Article (6) 6
Web Resource (6) 6
Reference (3) 3
Data Set (2) 2
Paper (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17030) 17030
female (8774) 8774
male (8128) 8128
heparin - adverse effects (6819) 6819
middle aged (6261) 6261
index medicus (5674) 5674
aged (5484) 5484
heparin (5375) 5375
anticoagulants - adverse effects (5207) 5207
heparin - therapeutic use (4531) 4531
anticoagulants - therapeutic use (4410) 4410
adult (4323) 4323
heparin - administration & dosage (3159) 3159
thrombocytopenia - chemically induced (3133) 3133
risk factors (2900) 2900
hematology (2854) 2854
molecular-weight heparin (2757) 2757
anticoagulants - administration & dosage (2735) 2735
treatment outcome (2661) 2661
peripheral vascular disease (2448) 2448
anticoagulants (2379) 2379
surgery (2342) 2342
thrombosis (2339) 2339
cardiac & cardiovascular systems (2076) 2076
hemorrhage - chemically induced (1985) 1985
heparin, low-molecular-weight - therapeutic use (1762) 1762
animals (1748) 1748
aged, 80 and over (1689) 1689
heparin, low-molecular-weight - adverse effects (1685) 1685
time factors (1656) 1656
prevention (1613) 1613
unfractionated heparin (1562) 1562
retrospective studies (1516) 1516
prospective studies (1490) 1490
venous thromboembolism (1425) 1425
thromboembolism (1400) 1400
medicine, general & internal (1377) 1377
heparin-induced thrombocytopenia (1301) 1301
deep-vein thrombosis (1278) 1278
fibrinolytic agents - therapeutic use (1270) 1270
anticoagulation (1217) 1217
pregnancy (1205) 1205
thrombosis - prevention & control (1200) 1200
thromboembolism - prevention & control (1135) 1135
therapy (1127) 1127
thrombosis - etiology (1075) 1075
thrombocytopenia (1062) 1062
fibrinolytic agents - adverse effects (1061) 1061
risk (1058) 1058
adolescent (1027) 1027
postoperative complications - prevention & control (1026) 1026
pharmacology & pharmacy (997) 997
heparin, low-molecular-weight - administration & dosage (990) 990
enoxaparin (979) 979
complications (967) 967
management (948) 948
cardiopulmonary bypass (943) 943
care and treatment (897) 897
drug therapy (892) 892
heparin - pharmacology (859) 859
warfarin (852) 852
venous thrombosis - prevention & control (849) 849
risk assessment (841) 841
health aspects (837) 837
dose-response relationship, drug (828) 828
incidence (824) 824
drug therapy, combination (811) 811
abridged index medicus (792) 792
prophylaxis (789) 789
thrombocytopenia - diagnosis (785) 785
diagnosis (783) 783
warfarin - therapeutic use (770) 770
follow-up studies (756) 756
blood coagulation - drug effects (741) 741
venous thrombosis (738) 738
venous thromboembolism - prevention & control (719) 719
thrombosis - drug therapy (710) 710
recombinant proteins - therapeutic use (707) 707
medicine & public health (702) 702
pulmonary-embolism (702) 702
glycosaminoglycans (701) 701
platelet aggregation inhibitors - therapeutic use (690) 690
pulmonary embolism (687) 687
venous thrombosis - drug therapy (681) 681
recurrence (674) 674
mortality (665) 665
child (660) 660
venous thrombosis - etiology (656) 656
pulmonary embolism - drug therapy (653) 653
platelet count (651) 651
randomized controlled trials as topic (648) 648
respiratory system (639) 639
analysis (635) 635
antibodies (635) 635
drug administration schedule (635) 635
warfarin - adverse effects (633) 633
research (626) 626
complications and side effects (617) 617
myocardial infarction - drug therapy (611) 611
thrombocytopenia - drug therapy (608) 608
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (10) 10
Online Resources - Online (7) 7
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Pharmacy (1) 1
Credit Valley Hospital - Closed Orders (1) 1
Scarborough Hospital - General (1) 1
Stacks (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
University Archives - Archives (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17140) 17140
German (740) 740
French (677) 677
Spanish (214) 214
Japanese (156) 156
Russian (114) 114
Italian (107) 107
Chinese (56) 56
Polish (43) 43
Swedish (27) 27
Dutch (25) 25
Czech (24) 24
Danish (24) 24
Hungarian (24) 24
Norwegian (20) 20
Portuguese (14) 14
Croatian (11) 11
Romanian (11) 11
Turkish (11) 11
Serbian (9) 9
Finnish (7) 7
Hebrew (7) 7
Korean (4) 4
Afrikaans (3) 3
Slovak (3) 3
Bulgarian (2) 2
Bosnian (1) 1
Lithuanian (1) 1
Slovenian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, 2012, Handbook of Experimental Pharmacology, ISBN 3642230555, Volume 207, Issue 207
Book Chapter
The New England Journal of Medicine, ISSN 0028-4793, 06/2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 141, Issue 2, pp. e24S - e43S
This article describes the pharmacology of approved parenteral anticoagulants. These include the indirect anticoagulants, unfractionated heparin (UFH),... 
RESPIRATORY SYSTEM | CRITICAL CARE MEDICINE | Heparitin Sulfate - adverse effects | United States | Humans | Thrombin - antagonists & inhibitors | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Dose-Response Relationship, Drug | Pipecolic Acids - administration & dosage | Chondroitin Sulfates - adverse effects | Societies, Medical | Pipecolic Acids - adverse effects | Heparitin Sulfate - administration & dosage | Polysaccharides - administration & dosage | Thrombosis - blood | Thrombosis - prevention & control | Dermatan Sulfate - administration & dosage | Dermatan Sulfate - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Evidence-Based Medicine | Recombinant Proteins - administration & dosage | Antithrombins - agonists | Chondroitin Sulfates - administration & dosage | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Thrombosis - drug therapy | Heparin, Low-Molecular-Weight - administration & dosage | Infusions, Intravenous | Practice Guidelines as Topic | Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed | American College of Chest Physician Evidence-Based Clinical Practice Guidelines Online Only
Journal Article
Seminars in Thrombosis and Hemostasis, ISSN 0094-6176, 11/2012, Volume 38, Issue 8, pp. 884 - 892
Journal Article
by Büller, Harry R and Prins, Martin H and Lensin, Anthonie W. A and Decousus, Hervé and Jacobson, Barry F and Minar, Erich and Chlumsky, Jaromir and Verhamme, Peter and Wells, Phil and Agnelli, Giancarlo and Cohen, Alexander and Berkowitz, Scott D and Bounameaux, Henri and Davidson, Bruce L and Misselwitz, Frank and Gallus, Alex S and Raskob, Gary E and Schellong, Sebastian and Segers, Annelise and Berkowitz, Scott and Gallus, Alexander and Lensing, Anthonie W. A and Haskell, Lloyd and Raskob, Gary and Bauersachs, Rupert and van Bellen, Bonno and Boda, Zoltán and Borris, Lars and Brenner, Benjamin and Brighton, Tim and Davidson, Bruce and Decousus, Herve and Eriksson, Henry and Jacobson, Barry and Kakkar, Ajay and Kwong, Yok-Lam and Lee, Lai Heng and Meijer, Karina and van der Meer, Jan and Monreal, Manuel and Piovella, Franco and Sandset, Per Morten and Smith, Mark and Tomkowski, Witold and Wang, Yuqi and Brandjes, Dees and Mac Gillavry, Melvin and Otten, Hans-Martin and Carlsson, Anders and Laporte, Silvy and Schulman, Sam and Gent, Michael and Turpie, Alexander and Martinelli, Ida and Lensing, Anthonie W and Muhlhofer, Eva and Tewes, Miriam and Trajanovic, Mila and Muller, Karin and Kim, Calvin and Gebel, Martin and Benson, Alice and Pap, Akos Ferenc and Goie, Juliette and Horvat-Broecker, Anea and Spadari, Giovanni and Peters-Wulf, Cornelia and Roig, J and Baker, R and Bianchi, A and Blombery, P and Brighton, T and Campbell, P and Carroll, P and Geraghty, R and Chong, B and Ramanathan, S and Archis, C and Coughlin, P and Salem, H and Crispin, P and Dean, M and Soni, R and Denaro, C and Kubler, P and Coghlan, D and Gallus, A and Gan, T. Eng and Tran, H and Coleman, C and Jackson, D and Khalafallah, A and Leahy, M and Leyden, M and Leyden, D and Sturtz, C and McCann, A and Gibbs, H and McRae, S and Richards, B and ... and The EINSTEIN–PE Investigators and EINSTEIN-PE Investigators and EINSTEIN–PE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
by Schulman, Sam and Kakkar, Ajay K and Goldhaber, Samuel Z and Schellong, Sebastian and Eriksson, Henry and Mismetti, Patrick and Christiansen, Anita Vedel and Friedman, Jeffrey and Le Maulf, Florence and Peter, Nuala and Kearon, Clive and Schulman, S and Eriksson, H and Goldhaber, S and Kakkar, A and Kearon, C and Mismetti, P and Schellong, S and Bergqvist, D and Tijssen, J and Prins, M. [=Martin H.] and Robben, S and Büller, H and Otten, H. M and Brandjes, D and Peters, R and Mac Gillavry, M. R and Gan, E and Salem, H and Baker, R and Blomberry, P and Curnow, J and Annichino-Bizzacch, J. M and Brandao Panico, M. D and Timi Ribas, J. R and Fernandes Manenti, E. R and Miranda, F and Moraes, J and Raev, D and Mollov, M and Peneva, M and Milanov, S and Anderson, D and Crowther, M and Dolan, S and Eikelboom, J and Game, M and Kahn, S and Kassis, J and Ritchie, B and Solymoss, S and Rodger, M and Yeo, E and Milot, A and Klinke, P and Chen, W and Zhihong, L and Chunxue, B and Jinming, L and Jiwei, Z and Jie, C and Jina, K and Yuqi, W and Zhongqi, Y and Hua, W and Kejing, Y and Bonan, L and Yadong, Y and Changwei, L and Jin, Z and Yongcheng, D and Spinar, J and Maly, R and Cizek, V and Bercikova, J and Cervinka, P and Lang, P and Jirka, V and Oral, I and Reichert, P and Kotik, L and Pojsl, S and Klimovic, T and Husted, S and Nielsen, H and Friis, E and Skødebjerg Kristensen, K and Mottier, D and El Kouri, D and Bleher, Y and Leroux, L and Boda, Z and Sereg, M and Riba, M and Hiremath, J. S and Kareem, S and Banker, D. N and Gadkari, M and Parakh, R and Suresh, K. R and ... and RE-COVER II Trial Investigators
Circulation, ISSN 0009-7322, 2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
Chest, ISSN 0012-3692, 2004, Volume 126, Issue 3, pp. 338S - 400S
This article discusses the prevention of venous thromboembolism (VTE) and is part of the Seventh American College of Chest Physicians Conference on... 
Aspirin | Warfarin | Deep-vein thrombosis | Fondaparinux | Prophylaxis | Heparin | Low-molecular-weight heparin | Thromboembolism | Postoperative Complications - etiology | Pulmonary Embolism - prevention & control | Humans | Postoperative Complications - prevention & control | Heparin, Low-Molecular-Weight - adverse effects | Heparin - therapeutic use | Heparin - adverse effects | Heparin, Low-Molecular-Weight - therapeutic use | Dose-Response Relationship, Drug | Vitamin K - antagonists & inhibitors | Aspirin - adverse effects | Venous Thrombosis - prevention & control | Aspirin - therapeutic use | Drug Therapy, Combination | Polysaccharides - therapeutic use | Drug Administration Schedule | Risk Assessment | Polysaccharides - adverse effects | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Evidence-Based Medicine | Venous Thrombosis - etiology | Randomized Controlled Trials as Topic | International Normalized Ratio | Pulmonary Embolism - etiology | Dose-Response Relationship; Drug | Polysaccharides/adverse effects/therapeutic use | Pulmonary Embolism/etiology/prevention & control | Randomized Controlled Trials | Anticoagulants/adverse effects/therapeutic use | Aspirin/adverse effects/therapeutic use | Drug Therapy; Combination | Heparin/adverse effects/therapeutic use | Heparin; Low-Molecular-Weight/adverse effects/therapeutic use | Venous Thrombosis/etiology/prevention & control | Postoperative Complications/etiology/prevention & control | Vitamin K/antagonists & inhibitors
Journal Article
JAMA, ISSN 0098-7484, 04/2015, Volume 313, Issue 13, pp. 1336 - 1346
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2018, Volume 378, Issue 7, pp. 615 - 624
Journal Article
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article